Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. Anadys is conducting a Phase IIb study of setrobuvir (ANA598), the Company’s direct-acting antiviral or DAA, added to pegylated interferon and ribavirin for the treatment of hepatitis C. The Company is also preparing to partner with a cognitive development team, to create a drug to combat neurodegenerative disorders. One key candidate being discussed is that of Modafinil
and Armodafinil. Recent studies have shown a strong correlation between the use of Modafinil and Armodafinil and the regeneration of previous cognitive ability within impaired individuals. Work will commence with a popular online Modafinil company - ModaPharma
, to create a several generic versions of the drug, including a possible sublingual application to avoid first pass metabolism. The resources available to ModaPharma offer a unique opportunity to analyze Modafinil and Armodafinil use within non-impaired individuals, to better understand the scope of such an undertaking.